Article citationsMore>>
Campbell, N., Boustani, M., Limbil, T., Ott, C., Fox, C., Maidment. I., Schubert, C.C., Munger. S., Fick, D., Mille, D. and Gulati, R. (2009) The Cognitive Impact of Anticholinergics: A Clinical Review. Clinical Interventions in Aging, 4, 225-233.
https://doi.org/10.2147/CIA.S5358
has been cited by the following article:
-
TITLE:
Tiotropium Bromide/Olodaterol Related Acute Cognitive Impairments
AUTHORS:
Samer Alkhuja, Monika Girgis
KEYWORDS:
Cognitive Impairment, Stiolto, Tiotropium Bromide/Olodaterol, COPD
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.12 No.5,
May
18,
2023
ABSTRACT: Background: The use of anticholinergics has been on the rise. With the increase in population longevity, more medication-related cognitive impairments (ACIs) have been reported. These impairments result in significant morbidities. We present a case that stresses on the importance of being vigilant when prescribing anticholinergic medications, especially in the elderlies. Case Report: A case of ACIs related to the use of tiotropium bromide/olodaterol (Stiolto Respimat) is being reported in a 71-year-old white man with COPD. Treatment with budesonide 180 mcg/actuation, and tiotropium bromide/olodaterol (Stiolto Respimat) inhalers was initiated. Two days after initiating treatment, the patient developed ACIs which manifested by gait imbalance, short-term memory dysfunction, inability to remember his family members, or to take his medications. Tiotropium bromide/olodaterol (Stiolto Respimat) was discontinued. After three days, a full recovery of ACIs was reported. A month later, due to worsening dyspnea, the patient self-resumed the medicine. Similar ACIs were reported within two days of resuming treatment. Tiotropium bromide/olodaterol (Stiolto Respimat) was discontinued indefinitely. Full recovery of ACIs was reported. Conclusion: ACIs should be noted as a significant side effect of tiotropium bromide/olodaterol. Clinicians should be vigilant, when prescribing anticholinergic medications to elderlies.